Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Mouse TNFSF14 protein

Cat.No. : TNFSF14-2020M
Product Overview : Recombinant Mouse TNFSF14 protein was expressed in Escherichia coli.
  • Specification
  • Gene Information
  • Related Products
Description : The protein encoded by this gene is a member of the tumor necrosis factor (TNF) ligand family. This protein is a ligand for TNFRSF14, which is a member of the tumor necrosis factor receptor superfamily, and which is also known as a herpesvirus entry mediator (HVEM). This protein may function as a costimulatory factor for the activation of lymphoid cells and as a deterrent to infection by herpesvirus. This protein has been shown to stimulate the proliferation of T cells, and trigger apoptosis of various tumor cells. This protein is also reported to prevent tumor necrosis factor alpha mediated apoptosis in primary hepatocyte. Two alternatively spliced transcript variant encoding distinct isoforms have been reported.
Source : E.coli
Species : Mouse
Form : Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH7.4.
Bio-activity : Fully biologically active when compared to standard. The ED50 as determined by a cytotoxicity assay using human HT-29 cells is less than 2 μg/ml, corresponding to a specific activity of > 500 IU/mg in the presence of murine anti-polyHistidine monoclonal antibody and rHuIFN-γ.
Molecular Mass : Approximately 18.4 kDa, a single non-glycosylated polypeptide chain containing 168 amino acids.
Protein length : 168
AA Sequence : DGGKGSWEKLIQDQRSHQANPAAHL TGANASLIGIGGPLLWETRLGLAFL RGLTYHDGALVTMEPGYYYVYSKVQ LSGVGCPQGLANGLPITHGLYKRTS RYPKELELLVSRRSPCGRANSSRVW WDSSFLGGVVHLEAGEEVVVRVPGN RLVRPRDGTRSYFGAFMV
Endotoxin : Less than 1 EU/µg of rMuLIGHT/TNFSF14 as determined by LAL method.
Purity : >96% by SDS-PAGE and HPLC analysis.
Storage : Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 centigrade as supplied. 1 month, 2 to 8 centigrade under sterile conditions after reconstitution. 3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitution : We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in 100 mM HAc to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤-20 centigrade. Further dilutions should be made in appropriate buffered solutions.
Gene Name : TNFSF14
Official Symbol : TNFSF14
Synonyms : TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; LTg; HVEML; LIGHT; Ly113; HVEM-L;
Gene ID : 50930
mRNA Refseq : NM_019418
Protein Refseq : NP_062291
UniProt ID : Q9QYH9

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (7)

Ask a question
What are the primary changes induced by TNFSF14 in the tumor microenvironment? 05/19/2022

TNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.

What challenges remain in utilizing TNFSF14 for cancer immunotherapy? 07/02/2021

While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.

What does TNFSF14 stand for? 02/05/2021

TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.

How can TNFSF14 synergize with other immunotherapy modalities? 02/22/2020

TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.

In what context has TNFSF14 been utilized to combat cancer? 02/06/2018

TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.

How long has TNFSF14 been in pre-clinical development? 06/11/2017

TNFSF14 has been in pre-clinical development for over a decade.

What is the primary promise of TNFSF14 in the field of cancer immunotherapy? 08/15/2016

TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.

Customer Reviews (3)

Write a review
Reviews
07/28/2020

    The extended longevity of results gave us the confidence to delve deeper into complex biological processes.

    08/01/2018

      It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.

      06/19/2016

        The ability to obtain enduring results positively influenced the depth of our investigations.

        Ask a Question for All TNFSF14 Products

        Required fields are marked with *

        My Review for All TNFSF14 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends